Scarlet Feng
Of Counsel
Of Counsel
Hong Kong
Scarlet advises issuers and banks on capital markets transactions.
Her practice focuses on Hong Kong initial public offerings and debt offerings under Rule 144A and Regulation S, with deep sector strength in biotech, healthcare and real estate. She also advises on high-profile restructuring transactions.
Experience & capabilities
Selected matters
- Softcare Limited's US$306.6 million listing on the Main Board of the Hong Kong Stock Exchange
- Qyuns Therapeutics' US$30.5 million listing on the Main Board of the Hong Kong Stock Exchange
- MicroPort MedBot's US$266.3 million listing on the Main Board of the Hong Kong Stock Exchange MicroPort MedBot is the first HK-listed, top-tier Chinese surgical robot company
- Zhaoke Ophthalmology Limited's US$427.6 million listing on the Main Board of the Hong Kong Stock Exchange
- Ocumension Therapeutics' US$182.5 million listing on the Main Board of the Hong Kong Stock Exchange. Ocumension Therapeutics is the first HK-listed biotech specialized in ophthalmology
- Shimao Group Holdings Limited's restructuring of its offshore debt in the aggregate principal amount of approximately US$11.5 billion
- joint lead managers for Prologis, L.P.'s CNY1.5 billion “dim-sum” bond issuance and CNY1.35 billion “dim-sum” bond issuance
- Fosun International Limited's offshore bond issuances and tender offers
* Experience prior to joining the firm
Background
Scarlet is admitted to the New York State Bar and holds the PRC Legal Professional Qualification Certificate. She holds an LL.M. from Boston University and an LL.M. from Renmin University of China.
Scarlet is a native Mandarin speaker and fluent in English.
